Millions taking one of UK's most common medications could be saved from cancer, study suggests
Taking antidepressants could help the body fight off cancer, a study has suggested.
Experts found selective serotonin reuptake inhibitors (SSRIs), one of the most common types of the drug, were found to have significantly improved the ability of T cells to fight cancer and suppress tumour growth.
T cells are a type of white blood cell that play a major role in helping the immune system identify and kill infections and cancer cells.
'It turns out SSRIs don't just make our brains happier, they also make our T cells happier—even while they're fighting tumours,' said Dr Lili Yang, senior author of the new study at University of California.
'These drugs have been widely and safely used to treat depression for decades, so repurposing them for cancer would be a lot easier than developing an entirely new therapy,' she added.
Antidepressants are typically taken for mood disorders as the drug increase levels of serotonin—the brain's 'happiness hormone'—by blocking the activity of a protein called serotonin transporter, or SERT.
But the study sought to explore if this process could also influence other parts of the body including digestion, metabolism and immune activity.
The researchers, who published their findings in the journal Cell noticed that immune cells isolated from tumours had higher levels of serotonin-regulating molecules.
Dr Bo Li, another author of the study explained: 'SERT has one job—to transport serotonin.
'SERT made for an especially attractive target because the drugs that act on it—SSRIs—are widely used with minimal side effects.'
The researchers tested SSRIs in mouse and human tumour models representing melanoma, breast, prostate, colon and bladder cancer.
In lab tests on tumours the researchers found SSRI treatment reduced average tumour size by over 50 per cent and made the cancer-fighting T cells more effective at killing cancer.
'SSRIs made the killer T cells happier in the otherwise oppressive tumour environment by increasing their access to serotonin signals, reinvigorating them to fight and kill cancer cells,' said Dr Yang.
The researchers also found SSRIs boosted the effectiveness of existing cancer therapies.
They tested a combination of an SSRI and a treatment called anti-PD-1 antibody in mice with cancer.
This antibody therapy works by blocking immune checkpoint molecules that normally suppress immune cell activity, therefore allowing T cells to attack tumours more effectively.
By adding SSRIs to this researchers significantly reduced tumour size in all treated mice and even achieved complete remission in some cases.
People with depression are thought to have low levels of serotonin, though there is scientific debate over this, and SSRIs combat this by boosting these levels.
While the study suggested SSRIs could one day be used to help treat cancer others have linked their long term usage to health problems.
Some experts suspect that the drugs could be causing too much serotonin to be released, with negative consequences for people's health.
Previous studies have linked their use to health issues including heart problems in young people alongside long-term and even permanent sexual dysfunction.
Health service figures show antidepressants are one of the most commonly taken medications in the UK.
Official data suggests as 8.7 million people in England were prescribed the medication—about 15 per cent of the total population.
In the US an estimated one in eight people are currently taking an antidepressant, according to the Centers for Disease Control.
More than 400,000 people are diagnosed with cancer each year in the UK, according to Macmillan Cancer Support.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medical News Today
12 minutes ago
- Medical News Today
Psilocybin for IBS: Could altering the mind help alter the gut?
Could magic mushrooms help relieve symptoms and treat IBS? A new study aims to find out. Irina Efremova/Stocksy Irritable bowel syndrome (IBS) is one of the most common conditions affecting the gut. Despite its prevalence and decades of research, treatments are limited, and the underlying causes remain shrouded in mystery. An ongoing study, conducted by Erin Mauney, MD, is taking a fascinating new approach to this mysterious condition: psychedelics, and more specifically psilocybin. In this article, we will investigate why researcher Erin Mauney believes psilocybin — the active compound in magic mushrooms — might help treat irritable bowel syndrome (IBS), and how her ongoing research is breaking new ground. To help us understand how altering the mind might alter the gut, we will first explore the links between body and brain. Historically — and, to a certain extent, still today — the mind and body have been considered separate. As science has progressed, it has become increasingly clear that, of course, the mind is part of the body. There is no separation. The brain is in tight communication with the body at all times via nerves and chemicals, like hormones and neurotransmitters, and the body talks back in the same language. This two-way interaction is perhaps most pronounced between the brain and the gut. The enteric nervous system (the nervous system of the gut) is the second-largest nervous system in the body after the brain. Some experts even refer to the gut as our 'second brain.' Although the enteric nervous system evolved first, so we could consider it the ' first brain .' Aside from their shared ancient pedigree, why would the gut and brain share such a tight link? In our modern world, where we are never more than 20 meters from a bagel, it is easy to forget that life on the Savannah millennia ago was much less convenient. The gut needed to tell the brain when it required refilling with enough time to hunt, scavenge, or forage for its next meal. As the food is ingested, the brain needs to ask the gut to ramp up its operations and prepare to digest. This relationship helps explain why we can feel longing in the pit of our stomach, and butterflies dance in our intestines when we feel excited: The gut and brain are in cahoots. Speaking in a recent interview, published in the journal Psychedelics , Mauney explains how, during her gastroenterology training, she 'became aware of how common trauma, especially early life trauma, is in the human experience.' 'Although there is more discussion in pediatrics about the cumulative effects of toxic stress over the lifespan,' she continues, 'I think overall this is an area that medicine, particularly gastroenterology and obesity medicine, really fails to understand and address meaningfully.' This piqued her interest in psychological approaches to gut issues. These links have led researchers to believe that IBS has a strong gut-brain component. Mauney and colleagues are currently embarking on the first-ever study to investigate whether talking therapy in conjunction with psilocybin might help relieve symptoms of IBS. Speaking in an interview with the Journal of Clinical Gastroenterology ( JC G), Mauney explained that around 60% of people with IBS do not respond to first-line therapies, such as dietary interventions or medications. So, the scientists recruited people with IBS who had already tried a wide range of approaches without experiencing significant benefits. This, she explains, included talking therapies, mind-body therapies, dietary changes, and drugs. In her JC G interview, Mauney explains how psilocybin acts 'transdiagnostically.' In other words, it can alter a range of psychological domains that are common across multiple mental health conditions. For instance, she explains how the drug can influence psychological characteristics such as: Rigidity: An inability to adapt or change. An inability to adapt or change. Rumination: Dwelling on negative thoughts and feelings. Dwelling on negative thoughts and feelings. Anxious over-focus on the self: A preoccupation with personal matters, while almost forgetting the outside world. She also says that psychedelics like psilocybin can help some people shift ingrained thought patterns, which is another facet of many mental health conditions, and some people with IBS. Beyond the psychological aspects of psilocybin treatment, Mauney also has some gut-focused theories. As the gut digests food, it squeezes, swells, deflates, and so on. For most people, these movements cause no distress or go unnoticed. For people with IBS, however, these routine movements may cause discomfort or pain. This is called visceral hypersensitivity. Research in animals suggests that a subtype of serotonin receptors in the gut, called 5HT2a receptors, might play a role in visceral hypersensitivity. Why does this matter? Psilocybin primarily works by activating 5HT2a receptors — so, perhaps it might reduce these uncomfortable sensations. Aside from this link, as Mauney explains in her JCG interview, scientists have also explored whether psilocybin might reduce pain in general. For instance, researchers have examined, with differing results, whether psilocybin could help in the treatment of migraine headaches, chronic neuropathic pain, fibromyalgia, and more. Because IBS causes visceral pain, this is yet another potential mechanism by which it may impart benefits. With its potential to influence psychology, visceral hypersensitivity, pain, and inflammation, psilocybin is a hopeful candidate for the treatment of IBS. Now, we just need to see the data. Mauney and colleagues' ongoing study was halfway through enrollment as of her April 24th JC G interview. Although she was cautious not to preempt the findings, Mauney was excited to share that at least some of the participants had experienced benefits. In the study, participants are paired with two medical professionals with backgrounds in psychotherapy or psychiatry. Each of the two therapy sessions (two weeks apart) involves the 'dosing' part of the study, where the participant takes psilocybin and relaxes while listening to a carefully curated playlist. Then, the three of them discuss the participants' symptoms, previous life experiences, and whatever comes up during the session. In total, these sessions last 6–8 hours. Mauney explains how the psilocybin 'acts as an amplifier of therapeutic processes,' perhaps enhancing standard talking therapy. Although this approach has not worked for everyone in the trial, for some, Mauney says, it has. She explains that it has encouraged some individuals to engage deeply with difficult parts of their lives, make meaningful changes that they could not manage before, or influence close relationships in ways that have led to reduced symptoms. For others, their symptoms have remained unchanged, but they report that the symptoms are no longer so bothersome. Medical News Today reached out to Ruvini Wijetilaka, MD, a board certified Internal Medicine Physician at Mecca Health, who was not involved in the study. 'As a physician, I find this early research into psilocybin-assisted therapy for treatment-resistant IBS intriguing and encouraging,' she explained. 'IBS is a complex condition rooted in the brain-gut connection,' she continued, 'and traditional treatments don't always work for everyone.' 'In cases where symptoms persist despite initial interventions, psilocybin may offer a promising alternative for targeting the neurological pathways involved. It's an exciting area of exploration for patients who experience chronic, unrelenting symptoms and have few remaining options.' — Ruvini Wijetilaka, MD Mauney's study is the first to look at this relationship, and the preliminary results are encouraging. However, as she explains, the study is not yet complete, and it might not work. With that said, because the mechanistic theory is promising, and it seems that at least some people have already benefited, we might be forgiven for being optimistic. 'It might sound a little bit out there to the average gastroenterologist,' says Mauney. 'But I think this is really what's needed, and what our patients are calling out for. […] A holistic approach to their suffering.' 'People with IBS that are not responding to available treatments need more options. Under the right conditions, psychedelics are worth a try for this group,' he said. However, he also suggested comparing its efficacy with Emotional Awareness and Expression Therapy (EAET), which he told us has had some success in the treatment of 'people with chronic musculoskeletal pain, back pain (when combined with mindfulness), and long COVID.' Psilocybin is unlikely to work for everyone, but Mauney hopes that, at least for some, this intervention could improve thought processes and relieve the negative impact of a chronic condition that remains poorly understood. 'While more concrete research is needed on this, the study could mark a meaningful shift in how we approach IBS care and gut health as a whole,' concluded Wijetilaka.
Daily Mail
16 minutes ago
- Daily Mail
Urgent nationwide recall of 1.7m popular home appliances as 17 people are poisoned
A wildly popular home appliance used in millions of American households has been urgently recalled after it was found to be exposing people to dangerous mold growth. Officials say at least 152 customers have reported mold contamination in the units, with 17 of them falling ill. An investigation is underway to determine the source and full scope of the outbreak. Midea, a major appliance manufacturer, pulled approximately 1.7 million U and U+ window air conditioners from the US market on June 5, following reports of mold contamination. The brand names included in the recall are: Midea, Comfort Aire, Danby, Frigidaire, Insignia, Keystone, LBG Products, Mr Cool, Perfect Aire, and Sea Breeze. These names appear on the front of the units, while the model number can be found on a label located on the front right side when facing the appliance. The products were sold through major retailers both in physical stores and online, including Costco, Best Buy, Home Depot, Menards, and from March 2020 to May 2025 for $280 to $500. Each unit is white and measures approximately 22 inches wide by 14 inches high. According to the CPSC, they were sold under 13 different brand names. The US Consumer Product Safety Commission (CPSC) issued a warning that the affected units have drainage issues, which can cause water to pool inside the machines, creating the perfect conditions for mold growth. Pictured are the recalled air conditioners and model numbers 'Pooled water in the air conditioners can fail to drain quickly enough, which can lead to mold growth,' the CPSC said in a statement. Exposure to mold can result in respiratory infections, allergic reactions, and other health issues, especially for individuals with underlying health conditions. Mold is a type of fungus that thrives in moist environments and can release harmful allergens or toxins into the air. Affected customers are eligible for either a free repair or a refund, depending on the model and date of purchase. 'Consumers who want a refund will be asked to return the unit using a free shipping label, or they may submit a photograph showing that they've cut the unplugged power cord to qualify for the refund,' the CPSC explained. Federal officials are urging consumers to stop using the recalled units immediately, particularly if anyone in the household is experiencing symptoms consistent with mold exposure. The recalled units come in three sizes, capable of cooling rooms at 8,000, 10,000, or 12,000 British Thermal Units (BTUs). They were manufactured in China and Thailand by GD Midea Air-Conditioning Co, Ltd. Each unit was sold with a remote control and can also be operated via a mobile app. The specific issue lies in the internal drainage system. If the reservoir does not empty quickly enough, stagnant water can accumulate, leading to mold growth inside the appliance. As the mold builds up, the unit may begin dispersing spores into the air, posing a health hazard for anyone nearby. Mold exposure poses a heightened risk for individuals with chronic respiratory issues such as asthma, lung disease, or weakened immune systems. According to the CDC, common symptoms of mold exposure include a stuffy nose, wheezing, fatigue, and red or itchy eyes or skin. Severe cases may result in fever or difficulty breathing. 'People with asthma or who are allergic to mold may have severe reactions,' the CDC states. 'Immunocompromised people and people with chronic lung disease may get infections in their lungs from mold.' Consumers who choose to continue using their air conditioner while waiting for a repair should follow the safety inspection instructions provided on Midea's recall page. To begin the refund or repair process, visit the Midea recall website or call 888-345-0251 between 8 am and 5 pm ET, Monday through Friday. The official recall number issued by the Consumer Product Safety Commission is 25-320.
Telegraph
29 minutes ago
- Telegraph
The proof that older people are getting smarter
Fitter, faster, stronger – and smarter. I'm paraphrasing, but that's how researchers at the International Monetary Fund (IMF) recently summed up the Baby Boom generation in a recent report on the consequences of global ageing. The developed world may be running out of lithe young things to drive our economies forward as birth rates collapse, but the oldies that remain are brainier than any generation before and can pick up at least some of the slack, it said. The IMF's findings rely on data from 41 advanced and emerging market economies and show that, on average, older people from around the age of 50 are smarter or more cognitively able today than ever before. Moreover, of all the indicators of healthy ageing (better retained agility, flexibility, strength, stamina etc), it is an improvement in our mental capacities that is most marked in the data, says the IMF. 'We aim to offer a new perspective on the old argument that ageing will lead inevitably to slumping economic growth and mounting fiscal pressures', say Bertrand Gruss and Diaa Noureldin, lead authors of the new report. 'When it comes to cognitive capacities, the 70s are indeed the new 50s: A person who was 70 in 2022 had the same cognitive health score as a 53 year old in 2000. Older workers' physical health – such as grip strength and lung capacity – has also improved.' The IMF aren't the only people who have looked at this trend. A 2022 study from the University of Wisconsin-Madison in the US shows that when it comes to brain power, Baby Boomers (born between 1946 to 64) beat the Great Generation (1901-27) on all the researchers' key measures of cognition. 'We found better age-adjusted performance in the cognitive domains of processing speed, executive function, attention and verbal fluency in more recent generations compared to the Greatest Generation', said its authors. So why is the world seemingly getting smarter? Professor Axel Börsch-Supan, director of the Munich Center for the Economics of Aging (MEA) at the Max Planck Institute for Social Law and Social Policy in Munich, said improvements in education have been key. 'That [Boomers] are smarter is essentially a function of their much better education than earlier generations ', he says. 'If you look at the years of schooling, that immensely increased in Europe, particularly in the Mediterranean countries, but also in the North and the East.' Education and better nutrition in childhood does not just help preserve good cognition in later years but improves employment prospects. And the longer you stay in employment, with all the mental and social stimulations that brings, the better things are for our brain health. Given the proportion of over 65s participating in the UK labour market has been slowly rising, and has more than doubled since 2000 participation was at 7.8 per cent over the first three months of that year, increasing to 15.7 per cent in 2025), no wonder our mental fire power is improving.
